Abstract
This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.
| Original language | English |
|---|---|
| Pages (from-to) | 398-409 |
| Number of pages | 12 |
| Journal | American Journal of Clinical Pathology |
| Volume | 129 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Antibody validation
- Breast hormonal receptors
- Progesterone receptor
- Quality assurance
- Rabbit monoclonal antibody
- SP2
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Cite this
Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2) : Findings of the UK national external quality assessment scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. / Ibrahim, Merdol; Dodson, Andrew; Barnett, Sarah; Fish, David; Jasani, Bharat; Miller, Keith.
In: American Journal of Clinical Pathology, Vol. 129, No. 3, 03.2008, p. 398-409.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2)
T2 - Findings of the UK national external quality assessment scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory
AU - Ibrahim, Merdol
AU - Dodson, Andrew
AU - Barnett, Sarah
AU - Fish, David
AU - Jasani, Bharat
AU - Miller, Keith
PY - 2008/3
Y1 - 2008/3
N2 - This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.
AB - This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.
KW - Antibody validation
KW - Breast hormonal receptors
KW - Progesterone receptor
KW - Quality assurance
KW - Rabbit monoclonal antibody
KW - SP2
UR - http://www.scopus.com/inward/record.url?scp=41649108476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41649108476&partnerID=8YFLogxK
U2 - 10.1309/2YXRLEQVPPNRWHGA
DO - 10.1309/2YXRLEQVPPNRWHGA
M3 - Article
VL - 129
SP - 398
EP - 409
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 3
ER -